Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 10/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9882261 | 0.88 | PIM1 (0.48) | PIM1PRKCQPRKCDROCK2ROCK1 | |
| SCHEMBL9882229 | 0.86 | PRKCQ (0.42) | PIM1PRKCQPRKCDPRKCA | |
| SCHEMBL9882216 | 0.83 | PRKCQ (0.54) | PIM1PRKCQPRKCDROCK2ROCK1 | |
| SCHEMBL9882295 | 0.82 | PRKCQ (0.41) | PIM1PRKCQPRKCDPRKCAPTPN11 | |
| SCHEMBL9882241 | 0.82 | PRKCQ (0.42) | PIM1PRKCQPRKCDPRKCA | |
| SCHEMBL9882220 | 0.82 | PRKCQ (0.42) | PIM1PRKCQPRKCDPRKCA | |
| SCHEMBL9882219 | 0.82 | PRKCQ (0.42) | PIM1PRKCQPRKCDPRKCA | |
| SCHEMBL9882133 | 0.81 | PRKCQ (0.48) | PRKCQPRKCDROCK2ROCK1CDC42BPA | |
| SCHEMBL9882283 | 0.80 | PRKCQ (0.41) | PIM1PRKCQPRKCDROCK2ROCK1 | |
| SCHEMBL9882265 | 0.80 | PRKCQ (0.41) | PIM1PRKCQPRKCDROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885PRKCQ 51/4885PRKCD 144/4885 |
| US-20120136000-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | PIM1 305/4885PRKCQ 51/4885PRKCD 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.